Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the promotion of Brendan Teehan to Executive Vice President and Chief Operating Officer, effective immediately. Previously the Senior Vice President, Chief Insights and Analytics Officer, Teehan will oversee all sales and marketing functions while continuing to lead commercial strategy and operations. Teehan has over 25 years of experience in healthcare, having worked with companies like Johnson & Johnson and Amgen. Additionally, two senior executives, Charmaine Lykins and Amanda Morgan, will leave the company for new opportunities.
Acadia Pharmaceuticals will report its third quarter 2021 financial results on November 8, 2021, after the market closes. A conference call and webcast will follow at 4:30 p.m. Eastern Time on the same day, providing insights into the company's financials and operations. Participants can access the call via dedicated numbers for U.S. and international callers. The event will also be available for replay until November 22, 2021. Acadia continues to focus on innovative solutions in neuroscience.
Acadia Pharmaceuticals (NASDAQ: ACAD) announced a scientific presentation on pimavanserin at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for November 9-12, 2021, in Boston, MA. A poster presentation will summarize post-hoc analysis results from the Phase 3 HARMONY trial, focusing on treating hallucinations and delusions in patients with Parkinson’s disease dementia. Although pimavanserin is FDA-approved for Parkinson’s disease psychosis, it is not approved for dementia-related psychosis.
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) will participate in several upcoming virtual investor conferences, including the Citi’s 16th Annual BioPharma Virtual Conference on September 10, 2021, Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 13, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021. Live webcasts will be accessible on the company’s website under the investors section, with archived recordings available for a month post-event.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced the departure of Elena Ridloff, Chief Financial Officer, effective September 10, 2021, as she transitions to another biopharmaceutical firm. Mark Schneyer, Senior VP of Business Development, will serve as interim CFO while a formal search for a new CFO is conducted. CEO Steve Davis expressed gratitude for Ridloff's contributions to Acadia's growth and the pimavanserin franchise.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 3:00 p.m. Eastern Time. The event will be held virtually, with a live webcast available on Acadia's website, www.acadia-pharm.com. An archived recording will be accessible until September 12, 2021. Acadia specializes in neuroscience, focusing on therapies for Parkinson's disease psychosis and exploring new treatments for dementia-related psychosis and other CNS disorders.
Acadia Pharmaceuticals (Nasdaq: ACAD) reported Q2 2021 financial results, with NUPLAZID sales reaching $115.2 million, a 5% increase year-over-year. The company is engaging with the FDA regarding pimavanserin for dementia-related psychosis after a recent Type A meeting. However, they face challenges in conducting further subgroup studies. R&D expenses decreased to $56.9 million, while SG&A expenses rose to $96.8 million. Acadia's net loss for Q2 was $43.9 million. Guidance for NUPLAZID sales has been reduced to $480-$515 million due to the pandemic impacting patient visits.
Acadia Pharmaceuticals announced positive results from the Phase 3 HARMONY study, published in the New England Journal of Medicine, evaluating pimavanserin for treating hallucinations and delusions in dementia-related psychosis (DRP). The study, involving 392 patients, showed a 2.8-fold reduction in relapse risk for those continuing pimavanserin compared to placebo (HR=0.35, p=0.005). Pimavanserin also proved well-tolerated with no cognitive decline. This represents a significant advancement in addressing an unmet need, as no FDA-approved treatments exist for DRP.
Acadia Pharmaceuticals (Nasdaq: ACAD) will release its second quarter 2021 financial results on August 4, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time to discuss these results. Participants can access the call via dial-in numbers or through a live webcast available on Acadia's website. The company continues to focus on neuroscience breakthroughs, particularly in developing therapies for conditions such as dementia-related psychosis and schizophrenia, while also noting the risks associated with drug development.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced three scientific presentations on dementia-related psychosis at the Alzheimer’s Association International Conference 2021, occurring July 26-30 in Denver and virtually.
The presentations include two studies on pimavanserin used alongside antidementia medications, focusing on safety outcomes and pharmacokinetic profiles. A third study will introduce a novel screening tool for psychosis in dementia.
These findings aim to enhance understanding and treatment strategies for patients with neurodegenerative conditions.